{"product_id":"therapeutic-monoclonal-antibodies-isbn-9780470117910","title":"Therapeutic Monoclonal Antibodies","description":"\u003cul\u003e \u003cli\u003e70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies.\u003c\/li\u003e \u003cli\u003eFirst book to address the discovery and development of antibody therapeutics in their entirety.\u003c\/li\u003e \u003cli\u003eMost chapters contain experimental data to illustrate the principles described in them.\u003c\/li\u003e \u003cli\u003eAuthors provide detailed methodologies that readers can take away with them and use in their own laboratories.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eForeword ix\u003c\/p\u003e \u003cp\u003ePreface xi\u003c\/p\u003e \u003cp\u003eContributors xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Antibody Basics\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Therapeutic Monoclonal Antibodies: Past, Present, and Future 3\u003cbr\u003e \u003ci\u003eWilliam R. Strohl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2. Antibody Molecular Structure 51\u003cbr\u003e \u003ci\u003eRobyn L. Stanfield and Ian A. Wilson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3. Glycosylation of Therapeutic IgGs 67\u003cbr\u003e \u003ci\u003eYusuke Mimura, Roy Jefferis, Yuka Mimura-Kimura, Jodie Abrahams, and Pauline M. Rudd\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4. Antibody Databases and Tools: The IMGTw Experience 91\u003cbr\u003e \u003ci\u003eMarie-Paule Lefranc\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Antibody Sources\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5. Human Antibodies from Transgenic Mice 117\u003cbr\u003e \u003ci\u003eNils Lonberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6. Rabbit Hybridoma 151\u003cbr\u003e \u003ci\u003eWeimin Zhu and Guo-Liang Yu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7. Human Antibody Repertoire Libraries 169\u003cbr\u003e \u003ci\u003eDavid Lowe and Tristan J. Vaughan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III In Vitro Display Technology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8. Antibody Phage Display 191\u003cbr\u003e \u003ci\u003eMichael Hust, Holger Thie, Thomas Schirrmann, and Stefan D\u003c\/i\u003e\u003ci\u003eübel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9. Yeast Surface Display 213\u003cbr\u003e \u003ci\u003eJennifer L. Lahti and Jennifer R. Cochran\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10. Ribosomal Display 239\u003cbr\u003e \u003ci\u003eGeorge Thom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11. Bacterial Display of Antibodies 255\u003cbr\u003e \u003ci\u003eThomas J. Van Blarcom and Barrett R. Harvey\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12. Antibody Selection from Immunoglobulin Libraries Expressed in Mammalian Cells 283\u003cbr\u003e \u003ci\u003eErnest S. Smith and Maurice Zauderer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Antibody Engineering\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13. Antibody Engineering: Humanization, Affinity Maturation, and Selection Techniques 311\u003cbr\u003e \u003ci\u003eJuan C. Almagro and William R. Strohl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14. Modulation of Serum Protein Homeostasis and Transcytosis by the Neonatal Fc Receptor 335\u003cbr\u003e \u003ci\u003eWilliam F. Dall’Acqua and Herren Wu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15. Engineering the Antibody Fc Region for Optimal Effector Function 349\u003cbr\u003e \u003ci\u003eGreg A. Lazar and John R. Desjarlais\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart V Physiology And In Vivo Biology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e16. Antibody-Complement Interaction 373\u003cbr\u003e \u003ci\u003eKileen L. Mershon and Sherie L. Morrison\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17. Bacteria Immunoglobulin-Binding Proteins: Biology and Practical Applications 385\u003cbr\u003e \u003ci\u003eLeslie Cope and Tessie McNeely\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18. Immunogenicity Screening Using in Silico Methods: Correlation between T-Cell Epitope Content and Clinical Immunogenicity of Monoclonal Antibodies 417\u003cbr\u003e \u003ci\u003eSi-Han Hai, Julie A. McMurry, Paul M. Knopf, William Martin, and Anne S. De Groot\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics 439\u003cbr\u003e \u003ci\u003eChristopher R. Gibson, Punam Sandhu, and William D. Hanley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20. Biodistribution and Imaging 461\u003cbr\u003e \u003ci\u003eTove Olafsen and Anna M. Wu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21. Antibodies and the Blood-Brain Barrier 483\u003cbr\u003e \u003ci\u003eAngela R. Jones and Eric V. Shusta\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart VI Antibody Characterization\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e22. Determination of Equilibrium Dissociation Constants 505\u003cbr\u003e \u003ci\u003eRobin E. Ernst, Katrina N. High, Tom R. Glass, and Qinjian Zhao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23. Molecular and Functional Characterization of Monoclonal Antibodies 525\u003cbr\u003e \u003ci\u003eQinjian Zhao, Terrance A. Stadheim, Lorenzo Chen, and Michael W. Washabaugh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24. Characterization of Heterogeneity in Monoclonal Antibody Products 541\u003cbr\u003e \u003ci\u003eYang Wang, Michael W. Washabaugh, and Qinjian Zhao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart VII Antibody Expression\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e25. Antibody Expression in Mammalian Cells 557\u003cbr\u003e \u003ci\u003eFubao Wang, Lorenzo Chen, Neal Connors, and Henryk Mach\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26. Production of Antibodies in Pichia pastoris 573\u003cbr\u003e \u003ci\u003eJuergen H. Nett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27. Production of Antibody Fab0 Fragments in E. coli 589\u003cbr\u003e \u003ci\u003eDavid P. Humphreys and Leigh Bowering\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28. Production of Human Therapeutic Monoclonal Antibodies in Chicken Eggs 623\u003cbr\u003e \u003ci\u003eLei Zhu and Robert J. Etches\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29. Production of Antibodies in Plants 651\u003cbr\u003e \u003ci\u003eKevin M. Cox, Jeffrey T. Regan, Jason D. Sterling, Vincent P. M. Wingate, and Lynn F. Dickey\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart VIII Therapeutic Antibodies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e30. The Formulation and Delivery of Monoclonal Antibodies 675\u003cbr\u003e \u003ci\u003eVikas K. Sharma, Hung-Wei Chih, Randall J. Mrsny, and Ann L. Daugherty\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31. Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates 711\u003cbr\u003e \u003ci\u003eNingyan Zhang, Brent R. Williams, Ping Lu, Zhiqiang An, and Chen-Ni Chin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32. Follow-On Protein Products: What, Where, When, How? 763\u003cbr\u003e \u003ci\u003eBrent R. Williams and William R. Strohl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33. Monomeric Fc Fusion Molecules 779\u003cbr\u003e \u003ci\u003eJennifer A. Dumont, Susan C. Low, Robert T. Peters, and Alan J. Bitonti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34. Radioimmunotherapy: Current Status and Future Directions 797\u003cbr\u003e \u003ci\u003eNeeta Pandit-Taskar and Chaitanya R. Divgi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35. Antibody-Drug Conjugate Therapy 821\u003cbr\u003e \u003ci\u003eStephen C. Alley, Dennis Benjamin, and Che-Leung Law\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAbbreviations 857\u003c\/p\u003e \u003cp\u003eIndex 865\u003c\/p\u003e   \u003cp\u003e\u003cb\u003eZHIQIANG AN, P\u003csmall\u003eH\u003c\/small\u003eD,\u003c\/b\u003e is the Chief Scientific Officer of Epitomics, Inc., in Burlingame, California. Previously, he was Director of Biologics Research at Merck Research Laboratories, West Point, Pennsylvania. Dr. An started his biotech\/pharmaceutical career at Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts. He received a doctor of philosophy degree from the University of Kentucky, Lexington, followed by postdoctoral training at the University of Wisconsin–Madison.   \u003c\/p\u003e\u003cp\u003e\u003cb\u003eBRINGS TOGETHER THE STATE OF KNOWLEDGE AND PRACTICE IN THERAPEUTIC MONOCLONAL ANTIBODIES\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThe first therapeutic antibody, murine-derived Muromonab OKT3®, was approved by the FDA in 1986 to treat acute organ rejection. Since then, monoclonal antibody therapeutics have played an increasing role in combating human diseases. To discover the state of the science and where this burgeoning field is heading, readers should turn to this 35-chapter work. It is the first book that draws together all the latest findings, tools, and practices that span the entire process of discovery, development, and clinical application of therapeutic monoclonal antibodies.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eTherapeutic Monoclonal Antibodies\u003c\/i\u003e reviews:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eBasic antibody biology and antibody sources\u003c\/li\u003e \u003cli\u003eAntibody engineering\u003c\/li\u003e \u003cli\u003ePhysiology and \u003ci\u003ein vivo\u003c\/i\u003e biology\u003c\/li\u003e \u003cli\u003eAntibody production and delivery\u003c\/li\u003e \u003cli\u003eAntibody therapeutic targets\u003c\/li\u003e \u003cli\u003eTherapeutic monoclonal antibodies in clinical use and in clinical trial\u003c\/li\u003e \u003cli\u003eBiogenerics\/biosimilars\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eChapters are written by one or more leading practitioners with hands-on experience in the area. The authors have provided not only theories but also methodologies that readers can use in their own laboratories. Moreover, experimental data is offered in most chapters to illustrate key principles.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eTherapeutic Monoclonal Antibodies\u003c\/i\u003e is recommended for biotechnologists, immunologists, medicinal and pharmaceutical chemists, bioengineers, bioprocess technologists, biochemists, and students. It will help them advance their own basic and clinical research by taking advantage of the latest findings in the discovery, development, and clinical application of therapeutic monoclonal antibodies.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47990381773029,"sku":"NP9780470117910","price":239.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470117910.jpg?v=1761787600","url":"https:\/\/k12savings.com\/es\/products\/therapeutic-monoclonal-antibodies-isbn-9780470117910","provider":"K12savings","version":"1.0","type":"link"}